Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumour features and responses to treatment with dihydroorotate dehydrogenase inhibitors
British Journal of Dermatology · 2025
DOI: 10.1093/bjd/ljaf253 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Lea Dousset und 19 weiteren Autor:innen. Beteiligte Einrichtung: University of Bordeaux, Inserm, BRIC, UMR 1312, Bordeaux, France. Hauptthemen laut MEDLINE: Skin Neoplasms, Oxidoreductases Acting on CH-CH Group Donors, Carcinoma, Squamous Cell, Enzyme Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fondation ARC pour la Recherche sur le Cancer, institutional, INSERM.
Abstract (Originalsprache)
Background
Alteration in metabolic activities is a critical step in cancer progression. Myriad metabolic-based therapy options are increasingly being proposed for human tumours. However, emerging evidence highlights interpatient metabolic heterogeneity and underscores the importance of metabolic phenotyping in cancer treatment.
Objectives
To investigate metabolic heterogeneity in cutaneous squamous cell carcinoma (cSCC) and its impact on cSCC characteristics and treatment responses.
Methods
We applied combined proteomic and bioenergetic analyses to patient samples representing various stages of cSCC, ranging from precancerous actinic keratosis to metastatic cSCC. To investigate the functional impacts of the identified metabolic heterogeneities on tumour characteristics and treatment responses, we used patient-derived tumour cell (PDC) and patient-derived xenograft (PDX) models by transplanting tumour cells and freshly resected patient tumours into immunocompromised mice.
Results
Three subgroups with low, medium and high metabolic scores, respectively, were identified across all stages of carcinogenesis. Functional analyses indicated that, in both models (PDC and PDX), the sensitivities of tumours to leflunomide, an inhibitor of dihydroorotate dehydrogenase (DHODH), were inversely correlated with their metabolic scores and directly correlated with DHODH protein expression level. Moreover, DHODH overexpression in nonresponding groups rendered them sensitive to leflunomide.
Conclusions
The findings demonstrate the relevance of metabolic profiling and scoring in the design of therapeutic approaches targeting the bioenergetic vulnerabilities of tumours and suggest DHODH as a promising therapeutic target in the low metabolic score subgroup of cSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Bordeaux, Inserm, BRIC, UMR 1312, Bordeaux, France.
- Dermatology Department, Bordeaux University Hospital, Saint-André Hospital, Bordeaux, France.
- University of Bordeaux, CNRS, IBGC, UMR 5095, Bordeaux, France.
- Animalerie A2, University of Bordeaux, Bordeaux, France.
- Inserm U1211 Maladies Rares: Génétique et Métabolisme (MRGM), University of Bordeaux, Bordeaux, France.
- CELLOMET, Bordeaux Centre of Functional Genomics, University of Bordeaux, Bordeaux, France.
ORCID-Profile: Domitille Chalopin-Fillot, Benjamin Dartigues, Nivea Amoedo, Stéphane Claverol, Marie-Laure Jullie, Alain Taieb, Laure Favot-Laforge, Marie Beylot-Barry, Macha Nikolski, Hamid-Reza Rezvani
Förderung
- Fondation ARC pour la Recherche sur le Cancer
- institutional
- INSERM
Zitieren
APA
Dousset, L., Khalife, F., Chalopin-Fillot, D., Dartigues, B., Naji, F., Mahfouf, W., Muzotte, E., Rousseau, B., Amoedo, N., Claverol, S., Bondaz, M., Beltzung, F., Jullie, M. L., Vergier, B., Taieb, A., Favot-Laforge, L., Rossignol, R., Beylot-Barry, M., Nikolski, M., & Rezvani, H. R. (2025). Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumour features and responses to treatment with dihydroorotate dehydrogenase inhibitors. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf253
Vancouver
Dousset L, Khalife F, Chalopin-Fillot D, Dartigues B, Naji F, Mahfouf W, et al. Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumour features and responses to treatment with dihydroorotate dehydrogenase inhibitors. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf253
BibTeX
@article{Dousset2025,
author = {Dousset, Lea and Khalife, Ferial and Chalopin-Fillot, Domitille and Dartigues, Benjamin and Naji, Fatima and Mahfouf, Walid and Muzotte, Elodie and Rousseau, Benoît and Amoedo, Nivea and Claverol, Stéphane and Bondaz, Mathieu and Beltzung, Fanny and Jullie, Marie-Laure and Vergier, Beatrice and Taieb, Alain and Favot-Laforge, Laure and Rossignol, Rodrigue and Beylot-Barry, Marie and Nikolski, Macha and Rezvani, Hamid-Reza},
title = {Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumour features and responses to treatment with dihydroorotate dehydrogenase inhibitors},
journal = {British Journal of Dermatology},
year = {2025},
doi = {10.1093/bjd/ljaf253}
}
EUVIMED